Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?

The introduction of anti-programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) checkpoint inhibitors has fundamentally changed the standard of care for most patients with metastatic non –small cell lung cancer (NSCLC). It has also provided the first survival increment in extensive disease small-cell lung cancer (SCLC) for more than two decades. A common aim of these immune modulating agents is to reinvigorate the host's immune response which has been shut down by various cancer-m ediated mechanisms.

Source: European Journal of Cancer - January 5, 2021 Category: Cancer & Oncology Authors: Niels Reinmuth, Martin Schuler Tags: Editorial Source Type: research